<DOC>
	<DOC>NCT02452606</DOC>
	<brief_summary>The purpose of this study is to investigate the genetic variants of clock and narcolepsy genes that determine the therapeutic effects of Stalevo® on the quality of sleep in patients with Parkinson's Disease.</brief_summary>
	<brief_title>Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>1. Patients diagnosed with PD in accordance with UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (Hughes AJ, et al. 1992). 2. Patients with PD who have wearing off phenomenon. 3. Patients with PD with Hoehn and Yahr stage 14. 4. Patients with PD who have sleep problems (PDSS score ≤120 or Epworth Sleepiness Scale(ESS) score ≥ 8). 5. Patients with PD who showed Montreal Cognitive Assessment (MoCA) score ≥15. 6. Patients with PD who have no major depression (Geriatric depression scale, GDS ≤ 24) 1. Secondary parkinsonism 2. Parkinsonplus syndromes (multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. 3. Patients with PD who have history of severe side effect of Stalevo®.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stalevo</keyword>
	<keyword>sleep disturbance</keyword>
	<keyword>central circadian clock</keyword>
	<keyword>narcolepsy</keyword>
</DOC>